Eli Lilly Zepbound Performance

Order byBest matchMost fresh

Zepbound beats Wegovy for weight loss

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial.

· 2d

EconoTimes · 2d

Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial

The Pharma Letter · 20h

Zepbound wins in weight loss duel

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study

A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy.

· 1d

This Drug Is Nearly 50 Percent More Effective Than Wegovy

· 1d

Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial

12don MSN

Zepbound Miss Hits Eli Lilly Shares: What’s Behind the Slump?

Investors and analysts will be watching closely how Lilly overcomes these obstacles in the changing obesity treatment environment.

12d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.

12don MSN

Why Eli Lilly Stock Is Sinking Today

Shares of Eli Lilly ( LLY -5.50%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.77%) gained 1% and the Nasdaq Composite ( ^IXIC -0.87%) gained 1.9%.

Morningstar13d

Eli Lilly Earnings: Solid Performance Overshadowed by Novo Nordisk's Obesity Coverage Win

Eli Lilly's first-quarter revenue grew 45% as combined sales for Mounjaro (diabetes) and Zepbound (obesity ... future competitors means that non-GAAP performance margin (similar to operating ...